Marker Therapeutics, Inc. (MRKR)

Over the past six months, Marker Therapeutics' stock has been influenced by its November 2025 earnings report, clinical trial updates for MT-601 in lymphoma and MT-401-OTS in AML/MDS, a pancreatic cancer study utilizing their MAR-T cell technology, a manufacturing collaboration with Cellipont Bioservices, a capital raise of approximately $10.0 million, and stock price fluctuations. The company reported its earnings results on November 13, 2025, with an EPS of ($0.12), surpassing the consensus estimate of ($0.69), and earned $1.23 million, exceeding analyst estimates of $0.72 million. The stock has experienced volatility, trading between $0.810 and $4.070 over the past 52 weeks.

As a clinical-stage biopharmaceutical company, Marker Therapeutics' products are not yet commercialized, so traditional demand seasonality does not apply. The "demand" for its therapies is driven by the enrollment and progress of patients in its clinical trials, and any "seasonality" is related to the timing of clinical trial milestones, data readouts, regulatory submissions, and funding cycles.

Marker Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on personalized T-cell immunotherapies for cancer, utilizing its Maestro™ platform to develop Multi-Antigen Recognizing (MAR) T cell therapies. Their lead product candidate, MT-601, is in Phase 1 study for lymphoma, while other candidates include autologous and allogeneic T cells, off-the-shelf products like MT-401-OTS, and peptide-based immunotherapeutic vaccines such as TPIV100/110 and TPIV200. The company's revenue primarily comes from non-dilutive funding sources.

Marker Therapeutics, Inc. conducts its research and development activities at its headquarters in Houston, Texas, and collaborates with academic and clinical partners across the United States.

Marker Therapeutics' brand reputation is influenced by its clinical trial progress and financial performance. Positive developments include encouraging Phase 1 APOLLO study results for MT-601 in lymphoma, the initiation of the RAPID study for MT-401-OTS, and promising pancreatic cancer study results. Challenges include a reported "challenging quarter ending June 2025" with declines in net sales and negative returns.

As of early February 2026, Marker Therapeutics, Inc. has 38 institutional owners and shareholders holding a total of 3,718,698 shares, representing 22.39% of the stock. Major institutional owners include NEA Management Company, LLC, Blue Owl Capital Holdings LP, and Vanguard Group Inc. Individual ownership accounts for 7.80% of the stock, with notable individual insiders including Enterprise Associates 16 New, Steve Elms, and Norman David Eansor.